Abstract The development of a ROS1 fusion as a bypass signaling pathway mediating resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) is rare, with only sporadic cases reported in the literature. Conse...www.frontiersin.orgZum Originalartikel
